3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Cardiotoxicity
7
Neoplasms
3
Heart Failure
3
Breast Neoplasms
3
Cardiovascular Diseases
2
Ventricular Dysfunction, Left
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Metabolic Syndrome
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Long QT Syndrome
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Diseases
1
Dyslipidemias
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Cardiomyopathies
1
Brugada Syndrome
1
Bone Marrow Diseases
1
Atrial Fibrillation
1
Arrhythmias, Cardiac
1
Interventions
Cyclophosphamide
81
fludarabine phosphate
77
Peripheral Blood Stem Cell Transplantation
62
Mycophenolic Acid
55
Tacrolimus
54
Whole-Body Irradiation
52
Busulfan
51
Antilymphocyte Serum
45
Cyclosporine
41
fludarabine
36
Methotrexate
32
Filgrastim
32
Melphalan
30
Radiotherapy
25
Methylprednisolone
19
Cytarabine
17
Cord Blood Stem Cell Transplantation
17
Sirolimus
15
Azacitidine
15
Granulocyte Colony-Stimulating Factor
14
Alemtuzumab
14
thymoglobulin
13
Flow Cytometry
13
Etoposide
13
Cyclosporins
13
Specimen Handling
10
Biopsy
10
Thiotepa
9
Psychiatric Rehabilitation
9
Decitabine
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Myeloproliferative Disorders
×
Electrocardiography
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled